Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
|Slideshows|November 18, 2019
How to Screen & Treat Depression in Patients with Cystic Fibrosis
Author(s)Veronica Hackethal, MD
The burden of poor mental health among CF patients is significant and impacts all aspects of disease management. Test yourself on international best practices for screening and treatment.
Advertisement
Rates of depression and anxiety among people with cystic fibrosis (CF) are known to be high. Prevalence of depression among children and adolescents ranges from ~8% to as high as 29% and among adults from 13% to 33%; prevalence of anxiety among adult CF patients has been found to range from 30% to 33%. Depression carries a risk for suicide and recent data from the Cystic Fibrosis Foundation Registry categorized 1.6% of recorded deaths as from suicide.
Advertisement
Related to this article
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
Advertisement
Advertisement
Trending on Patient Care Online
1
Stroke Incidence Nearly Doubled Among Adults Younger Than 55 Over 3 Decades
2
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
3
ACCORD Trials: Efficacy and Safety of Dextromethorphan-Bupropion in Agitation
4
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
5